Clinical Trial

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-08-17; most recent amendment 2025-07-21.
Status change: Recruiting → Active, Not Recruiting 2025-07-21
Status change: Enrolling by Invitation → Recruiting 2024-09-24
Status change: Not Yet Recruiting → Enrolling by Invitation 2023-10-16
Trial Details
NCT Number NCT06007677
Lead Sponsor Astria Therapeutics, Inc.
Conditions Hereditary Angioedema
Enrollment 56 participants
Start Date 2023-09-26
Primary Completion 2031-03 (estimated)
Study Completion 2031-03 (estimated)
Updated on ClinicalTrials.gov 2025-07-23